MedPath

Patient satisfaction and quality of vision following implantation of latest technology based Intraocular Lens implantation after cataract surgery in both eyes

Completed
Conditions
Age-related nuclear cataract,
Registration Number
CTRI/2020/08/027105
Lead Sponsor
Dr Sri Ganesh
Brief Summary

Through this study we would like to evaluate the clinical outcomes and quality of vision following bilateral implantation of a new Extended Depth of Focus (EDoF) Intraocular Lens - ZEISS AT LARA 829MP IOL

We would like to assess the spectacle independence for near, intermediate and distant vision.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

A patient with cataract for which phacoemulsification or femtolaser assisted cataract surgery with posterior chamber IOL implantation · Male or female in good general health, 40-80 years of age at the time of the pre-operative examination · A patient has the visual potential of 20/25 or better in each eye after cataract removal and IOL implantation · A patient with preoperative corneal astigmatism less than 1D and stable corneal conditions within the last 12 months · A patient with clear ocular media other than cataract in each eye · A patient with normal OCT of the macula in each eye.

Exclusion Criteria
  • A patient with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in either eye A patient with amblyopia or strabismus A patient with capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome) in either eye A patient has a history of significant ocular trauma or prior ocular surgery in either eye A patient with cornea guttata, corneal scarring, keratoplasty, irregular astigmatism (e.g. Keratoconus) A patient that may or is expected to undergo surgical intervention and/or ocular laser treatment prior to or during the study period in either eye Need for a dioptre out of the range of +16.0D to +26.0D A patient with any uncontrolled systemic disease.
  • A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study A patient currently participating or has participated within 30 days prior to the start of this study in a drug or other investigational research study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bilateral,unilateral uncorrected distance visual acuity and Distance corrected visual1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
acuity with ETDRS chart at 4 m1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Bilateral uncorrected and distance corrected intermediate visual acuity and reading speeds at 60 and 80 cm1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
with Salzburg Reading Desk(SRD)1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Bilateral uncorrected and distance corrected near vision with ETDRS chart and SRD at 40 cm1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Defocus curves from +2 to -3 D1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Contrast sensitivity with CSV 1000 chart.1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Subjective Questionnare for dysphotopsia and spectacle independence1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR
Secondary Outcome Measures
NameTimeMethod
Spectacle independence for distance, intermediate and near vision1 WEEK, 1 MONTH, 3 MONTHS, 6 MONTHS AND 1 YEAR

Trial Locations

Locations (1)

Nethradhama Superseciality Eye Hospital

🇮🇳

Bangalore, KARNATAKA, India

Nethradhama Superseciality Eye Hospital
🇮🇳Bangalore, KARNATAKA, India
Dr Sri Ganesh
Principal investigator
9845129740
phacomaverick@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.